Several stocks were obtained from Exelixis where the presence of a deletion could not be verified by complementation tests with mutations in the Bloomington collection (see FBrf0219608). One of these was Df(2L)Exel9064. Recently, Ellen Popodi was able to show with PCR amplifications that the expected deletion was not present in the stock. It is likely that the deletion was never present and that the chromosome was a false positive in preliminary verification tests at Exelixis.